GlassScriptPhysician profile
Abraham Ramos
NPI 1962846758
$1,125.63
in general payments reported to CMS, 2019-2025
12 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2024: $486 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $44.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.73 |
| Education | $44.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $204.17 | 2024-2025 | Farxiga |
| Medtronic Vascular, INC. | $182.46 | 2019 | |
| Amgen INC. | $156.70 | 2019-2025 | Krystexxa |
| Calliditas Therapeutics US INC. | $127.57 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $120.55 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $58.33 | 2024-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $55.10 | 2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $54.02 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $47.17 | 2024 | Jynarque |
| Akebia Therapeutics INC | $46.62 | 2024 | Vafseo, Auryxia |
| Ardelyx, INC. | $45.00 | 2024 | Ibsrela |
| Kyowa Kirin, INC. | $27.94 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.